MDGL Q3 2024 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$62M

Gross Profit

$60M96.5% margin

Operating Income

-$116M-187.1% margin

Net Income

-$107M-172.0% margin

EPS (Diluted)

$-4.92

QoQ Revenue Growth

+324.8%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$68M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$296M

Stockholders' Equity

$777M

Cash & Equivalents

$233M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$62M	$0	—
Gross Profit	$60M	$0	—
Operating Income	-$116M	-$99M	-18.0%
Net Income	-$107M	-$99M	-8.3%